205 related articles for article (PubMed ID: 37870961)
41. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.
Oliveira C; Velho S; Moutinho C; Ferreira A; Preto A; Domingo E; Capelinha AF; Duval A; Hamelin R; Machado JC; Schwartz S; Carneiro F; Seruca R
Oncogene; 2007 Jan; 26(1):158-63. PubMed ID: 16953233
[TBL] [Abstract][Full Text] [Related]
42. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
[TBL] [Abstract][Full Text] [Related]
43. Loss of circadian gene Timeless induces EMT and tumor progression in colorectal cancer via Zeb1-dependent mechanism.
Colangelo T; Carbone A; Mazzarelli F; Cuttano R; Dama E; Nittoli T; Albanesi J; Barisciano G; Forte N; Palumbo O; Graziano P; di Masi A; Colantuoni V; Sabatino L; Bianchi F; Mazzoccoli G
Cell Death Differ; 2022 Aug; 29(8):1552-1568. PubMed ID: 35034102
[TBL] [Abstract][Full Text] [Related]
44. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
[TBL] [Abstract][Full Text] [Related]
45. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
46. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.
Yun J; Mullarky E; Lu C; Bosch KN; Kavalier A; Rivera K; Roper J; Chio II; Giannopoulou EG; Rago C; Muley A; Asara JM; Paik J; Elemento O; Chen Z; Pappin DJ; Dow LE; Papadopoulos N; Gross SS; Cantley LC
Science; 2015 Dec; 350(6266):1391-6. PubMed ID: 26541605
[TBL] [Abstract][Full Text] [Related]
47. Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer.
Kochi M; Hinoi T; Niitsu H; Miguchi M; Saito Y; Sada H; Sentani K; Sakamoto N; Oue N; Tashiro H; Sotomaru Y; Yasui W; Ohdan H
Cancer Sci; 2020 Oct; 111(10):3540-3549. PubMed ID: 32629543
[TBL] [Abstract][Full Text] [Related]
48. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
[TBL] [Abstract][Full Text] [Related]
49. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
[TBL] [Abstract][Full Text] [Related]
50.
Martianov AS; Mitiushkina NV; Ershova AN; Martynenko DE; Bubnov MG; Amankwah P; Yanus GA; Aleksakhina SN; Tiurin VI; Venina AR; Anuskina AA; Gorgul YA; Shestakova AD; Maidin MA; Belyaev AM; Baboshkina LS; Iyevleva AG; Imyanitov EN
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902296
[TBL] [Abstract][Full Text] [Related]
51. MicroRNA Expression in
Lundberg IV; Wikberg ML; Ljuslinder I; Li X; Myte R; Zingmark C; Löfgren-Burström A; Edin S; Palmqvist R
Anticancer Res; 2018 Feb; 38(2):677-683. PubMed ID: 29374690
[TBL] [Abstract][Full Text] [Related]
52. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
[TBL] [Abstract][Full Text] [Related]
53. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer.
Krebs AM; Mitschke J; Lasierra Losada M; Schmalhofer O; Boerries M; Busch H; Boettcher M; Mougiakakos D; Reichardt W; Bronsert P; Brunton VG; Pilarsky C; Winkler TH; Brabletz S; Stemmler MP; Brabletz T
Nat Cell Biol; 2017 May; 19(5):518-529. PubMed ID: 28414315
[TBL] [Abstract][Full Text] [Related]
54. Zinc finger E-box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition.
Liu Z; Sun B; Qi L; Li H; Gao J; Leng X
Cancer Sci; 2012 Apr; 103(4):813-20. PubMed ID: 22212097
[TBL] [Abstract][Full Text] [Related]
55. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
Weng WH; Leung WH; Pang YJ; Hsu HH
Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
[TBL] [Abstract][Full Text] [Related]
56. Novel Polymethoxylated Chalcones as Potential Compounds Against KRAS-Mutant Colorectal Cancers.
Mahmoud A; Elkhalifa D; Alali F; Al Moustafa AE; Khalil A
Curr Pharm Des; 2020; 26(14):1622-1633. PubMed ID: 32026770
[TBL] [Abstract][Full Text] [Related]
57. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
[TBL] [Abstract][Full Text] [Related]
58. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.
Zhang L; Zhang W; Li Y; Alvarez A; Li Z; Wang Y; Song L; Lv D; Nakano I; Hu B; Cheng SY; Feng H
Oncogene; 2016 Oct; 35(43):5641-5652. PubMed ID: 27041571
[TBL] [Abstract][Full Text] [Related]
59. The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.
He Z; Thorrez L; Siegfried G; Meulemans S; Evrard S; Tejpar S; Khatib AM; Creemers JWM
Oncogene; 2020 Apr; 39(17):3571-3587. PubMed ID: 32139876
[TBL] [Abstract][Full Text] [Related]
60. GRHL2 inhibits colorectal cancer progression and metastasis via oppressing epithelial-mesenchymal transition.
Yang Z; Wu D; Chen Y; Min Z; Quan Y
Cancer Biol Ther; 2019; 20(9):1195-1205. PubMed ID: 31063022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
